Clinical study on medical value of adoptive immunotherapy with chemotherapy for stage IV colorectal cancer
Ontology highlight
ABSTRACT: Interventions: Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2,p.o.(day1-14) Autologous alfa/beta T cells i.v. to be repeated every 3 weeks
Primary outcome(s): Safety
Study Design: Single arm Non-randomized
DISEASE(S): Colorectal Cancer
PROVIDER: 2626285 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA